The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00718666
First received: July 17, 2008
Last updated: June 5, 2014
Last verified: June 2014
  Purpose

In this study, the concentration of antibody to the vaccine one year, three and five years after vaccination in subjects who were vaccinated with GSK Biologicals' meningococcal vaccine GSK134612 in a previous study (whose objectives & outcome measures are presented in a separate protocol posting with NCT number =00471081) will be evaluated. The safety and immune response of a booster dose of vaccine GSK134612 administered at 5 years post-primary vaccination will also be evaluated. In addition, the immune response to a dose of vaccine GSK134612 administered to age-matched controls not previously given a meningococcal vaccine will be evaluated.

This protocol posting has been updated further to protocol amendment 2, dated 28 october 2010. The sections impacted are summary, study design, outcome measures, intervention, and eligibility criteria.


Condition Intervention Phase
Infections, Meningococcal
Biological: Meningococcal vaccine GSK134612
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: The Long Term Antibody Persistence Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Administered as 1 or 2 Doses to Healthy Toddlers at 9-12 Months of Age and as a Booster Dose at 5 Years Post-primary Vaccination

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Meningococcal hSBA antibody titers [ Time Frame: One year, three years, and five years after primary vaccination for primed subjects ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Meningococcal hSBA antibody titers [ Time Frame: One month post booster vaccination with GSK134612 vaccine at year 5 after primary vaccination for primed subjects ] [ Designated as safety issue: No ]
  • Meningococcal rSBA antibody titers [ Time Frame: One year, three years, and five years after primary vaccination and one month post booster vaccination with GSK134612 vaccine at year 5 after primary vaccination for primed subjects ] [ Designated as safety issue: No ]
  • Meningococcal ELISA antibody concentrations [ Time Frame: One year, three years, and five years after primary vaccination and one month post booster vaccination with GSK134612 vaccine at year 5 after primary vaccination for primed subjects ] [ Designated as safety issue: No ]
  • Occurrence of solicited local and general symptoms [ Time Frame: 4 days 5 (Day0-3) following the primary (naive control subjects) and booster vaccination ] [ Designated as safety issue: No ]
  • Occurrence of non-serious AEs [ Time Frame: 31 days (Day 0-30) following the primary (naive control subjects) and booster vaccination ] [ Designated as safety issue: No ]
  • Occurrence of serious AEs and new onset of chronic illness [ Time Frame: 6 months (Day 0-180) following the primary (naive control subjects) and booster vaccination ] [ Designated as safety issue: No ]
  • Meningococcal hSBA antibody titers [ Time Frame: Just before and one month post primary vaccination with GSK134612 vaccine for naive control subjects ] [ Designated as safety issue: No ]
  • Meningococcal rSBA antibody titers [ Time Frame: Just before and one month post primary vaccination with GSK134612 vaccine for naive control subjects ] [ Designated as safety issue: No ]
  • Meningococcal ELISA antibody concentrations [ Time Frame: Just before and one month post primary vaccination with GSK134612 vaccine for naive control subjects ] [ Designated as safety issue: No ]

Enrollment: 387
Study Start Date: October 2008
Study Completion Date: March 2014
Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group A
Subjects who were previously vaccinated with one dose of GSK134612 at 12 months of age.
Biological: Meningococcal vaccine GSK134612
One dose, as intramuscular injection
Experimental: Group B
Subjects who were previously vaccinated with two doses of GSK134612, one each at 9 and 12 months of age.
Biological: Meningococcal vaccine GSK134612
One dose, as intramuscular injection
Experimental: Group C
Subjects aged 5-6 years not previously administered meningococcal vaccine.
Biological: Meningococcal vaccine GSK134612
One dose, as intramuscular injection

Detailed Description:

GSK Biologicals has developed a meningococcal conjugate vaccine (GSK134612). This candidate vaccine has been shown to be well tolerated and immunogenic in toddlers.

The purpose of this study is to evaluate the antibody persistence at approximately 1 year, 3 years and 5 years post-administration of one dose or two doses of GlaxoSmithKline (GSK) Biologicals' meningococcal vaccine GSK134612 when given to healthy toddlers 9-12 months of age. To evaluate, the safety and immunogenicity of a booster dose of GSK134612 administered to all eligible subjects at 5 years after the primary vaccination. To evaluate the safety and immunogenicity in a new group of subjects aged 5-6 years (naive control group) who will receive a single dose of vaccine GSK134612.

  Eligibility

Ages Eligible for Study:   2 Years to 6 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

All subjects must satisfy the following criteria for the persistence phase of the study entry:

  • A male or female toddler who was vaccinated 1, 3 or 5 years ago with the last dose of MenACWY-TT in study with NCT number=00471081.
  • Written informed consent obtained from parents/guardian of the subject.
  • Healthy subjects as established by medical history before entering into the study.
  • Having completed the active phase of the vaccination study with NCT number=00471081 (i.e., not withdrawn, had received all planned doses of study vaccines, provided a post-vaccination blood sample after the final dose).

All subjects must meet the following criteria prior to receiving the booster vaccination:

  • Written informed consent obtained from parents/guardian of the subject.
  • Subjects who can and will comply with the requirements of the protocol.
  • Subjects who provide a blood sample 5 years after last vaccination in study with NCT number=00471081.

All subjects must satisfy the following criteria prior to enrollment in the naïve control group:

  • Subjects who the investigator believes can and will comply with the requirements of the protocol.
  • A male or female between, and including, 5-6 years of age at the time of the vaccination.
  • Written informed consent obtained from parents/guardian of the subject.
  • Healthy subjects as established by medical history and history-directed physical examination before entering into the study.

Exclusion Criteria:

Exclusion criteria for persistence study entry

  • Use of any investigational or non-registered product (drug or vaccine) within 30 days of each persistence timepoint.
  • Vaccination with meningococcal polysaccharide or conjugate vaccine of serogroup A, B, C, W-135, and/or Y outside of study with NCT number=00471081.
  • History of any meningococcal disease due to serogroup A, B, C, W-135, or Y.
  • Any confirmed or suspected immunosuppressive or immunodeficiency condition based on medical history and physical examination (no laboratory testing is required).
  • Administration of immunoglobulins and/or any blood products within the three months preceding each persistence timepoint.
  • Concurrently participating in another clinical study within 30 days of each persistence timepoint, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
  • Bleeding disorders, such as thrombocytopenia, or subjects on anti-coagulant therapy.
  • Subjects withdrew consent to be contacted for follow-up studies.

Exclusion criteria for primary (naive control)/booster vaccination at year 5 study entry (to be checked at Year 5)

  • Child in care.
  • Subjects who were enrolled in the Kaiser Healthcare system in study with NCT number=00471081, but are no longer enrolled.
  • Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the primary (naive control)/booster vaccination, or planned use during the study period.
  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the primary (naive control)/booster vaccination. (For corticosteroids, this will mean prednisone, or equivalent, >= 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
  • Vaccination with meningococcal polysaccharide or conjugate vaccine outside of study with NCT number=00471081.
  • History of any meningococcal disease.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history (no laboratory testing is required).
  • Administration of immunoglobulins and/or any blood products within the three months preceding the primary (naive control)/booster vaccination or planned administration during the study period.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
  • Bleeding disorders, such as thrombocytopenia, or subjects on anti-coagulant therapy.
  • Subjects withdrew consent to be contacted for follow-up studies.
  • Hypersensitivity to latex.
  • Previous administration or planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days of the study vaccination (primary vaccination for the naïve control group and booster vaccination for subjects primed in Study with NCT number = 00471081) and ending 30 days after with the exception of any licensed inactivated influenza vaccine (live attenuated influenza vaccine is not allowed).
  • Previous administration or planned administration of tetanus or any tetanus containing vaccine during the period starting from 30 days of the study vaccination and ending 30 days after.
  • A family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Major congenital defects or serious chronic illness.
  • History of any neurological disorders or seizures.
  • Acute disease at the time of vaccination. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e., temperature by any method < 99.5°F (37.5°C).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00718666

Locations
United States, Arkansas
GSK Investigational Site
Benton, Arkansas, United States, 72019
GSK Investigational Site
Little Rock, Arkansas, United States, 72205
United States, California
GSK Investigational Site
Antioch, California, United States, 94509
GSK Investigational Site
Fremont, California, United States, 94538
GSK Investigational Site
Hayward, California, United States, 94545
GSK Investigational Site
Santa Rosa, California, United States, 95403
GSK Investigational Site
Vacaville, California, United States, 95688
United States, Colorado
GSK Investigational Site
Lakewood, Colorado, United States, 30226
GSK Investigational Site
Littleton, Colorado, United States, 80123
GSK Investigational Site
Littleton, Colorado, United States, 80122
GSK Investigational Site
Westminster, Colorado, United States, 80234
GSK Investigational Site
Wheat Ridge, Colorado, United States, 80033
United States, Ohio
GSK Investigational Site
Canton, Ohio, United States, 44708
United States, Texas
GSK Investigational Site
Amarillo, Texas, United States, 79124
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided by GlaxoSmithKline

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00718666     History of Changes
Other Study ID Numbers: 112021
Study First Received: July 17, 2008
Last Updated: June 5, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
Safety
Vaccines, conjugate
Immunogenicity
Meningococcal vaccine
Booster vaccination
Primary vaccination
Neisseria meningitides
Toddlers
Humans
Meningococcal disease

Additional relevant MeSH terms:
Meningococcal Infections
Neisseriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections

ClinicalTrials.gov processed this record on August 25, 2014